Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Neoplasms

Explore clinical trials studying Triple Negative Breast Neoplasms. Study availability and eligibility vary by location and protocol.

819 public trials 296 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Neoplasms trial results

Completed

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT04742959

Conditions
Adenocarcinoma, Advanced Solid Tumor, Biliary Tract Diseases, +57 more
Locations
  • City of Hope Duarte, California, United States
  • The University of Chicago Chicago, Illinois, United States
  • Rutgers Cancer Institute New Brunswick, New Jersey, United States
  • Gabrail Cancer Center Research Canton, Ohio, United States
View Trial Details
Completed

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Cancer, +52 more
Locations
  • Sarah Cannon Research Institute at HealthOne Denver, Colorado, United States
  • Florida Cancer Specialists ORLANDO/DDU Lake Mary, Florida, United States
  • START Midwest Grand Rapids, Michigan, United States
  • Washington University Medical School St Louis, Missouri, United States
View Trial Details
Completed

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04177108

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • USA Mitchell Cancer Institute Mobile, Alabama, United States
  • Highlands Oncology Group Springdale, Arkansas, United States
  • UCLA Los Angeles, California, United States
  • Kaiser Permanente-SCPMG; Oncology Research San Diego, California, United States
View all 182 locations
View Trial Details
Completed

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

NCT03125902

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Florida Cancer Specialists; Department of Oncology Fort Myers, Florida, United States
  • Florida Cancer Specialist, North Region St. Petersburg, Florida, United States
  • Northwest Georgia Oncology Centers PC - Marietta Marietta, Georgia, United States
View all 161 locations
View Trial Details
Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NCT02648477

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +11 more
Locations
  • City of Hope Corona Corona, California, United States
  • City of Hope Medical Center Duarte, California, United States
  • City of Hope Antelope Valley Lancaster, California, United States
  • City of Hope Rancho Cucamonga Rancho Cucamonga, California, United States
View Trial Details
Completed

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

NCT05112536

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations
  • Cancer and Blood Specialty Clinic Los Alamitos, California, United States
  • UCLA Department of Medicine - Hematology/Oncology Santa Monica, California, United States
  • PIH Health Whittier, California, United States
  • Nebraska Hematology-Oncology, P.C. Lincoln, Nebraska, United States
View Trial Details

Related conditions